leflunomide

P1, N=23, Recruiting, Deborah Doroshow | Trial completion date: Dec 2027 --> Jul 2028

P=N/A, N=302, Completed, Sanofi | Active, not recruiting --> Completed | N=3500 --> 302

Mechanistic investigations uncovered that the tumor-suppressive effect of APCDD1 was mediated by promoter hypermethylation, and its expression could be restored by the demethylating agent Decitabine. We further propose Leflunomide as a novel therapeutic strategy for high-risk WT patients. These findings advance our understanding of WT biology and provide actionable insights for risk stratification and targeted intervention.

P4, N=202, Not yet recruiting, Sint Maartenskliniek Stichting

National centralized procurement policy achieved dramatic cost reductions (e.g., tofacitinib DDDc decreased by 93.3%), directly driving increased utilization of tsDMARDs and bDMARDs. This study provides empirical evidence that aggressive pharmaceutical pricing policies can rapidly improve access to advanced rheumatologic therapies in resource-limited settings, offering a replicable model for healthcare systems worldwide. Key Points • Overall disease-modifying antirheumatic drugs (DMARDs) use showed modest growth from 2018 to 2022. • tsDMARDs and bDMARDs exhibited rapid increases in use and revenue. • Methotrexate and leflunomide remained key csDMARDs in clinical practice.

P=N/A, N=50, Active, not recruiting, King Chulalongkorn Memorial Hospital | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Jul 2028 | Trial primary completion date: Dec 2025 --> Dec 2027

This comprehensive pharmacovigilance study mapped drug-MC associations, suggesting potential novel safety signals while corroborating previously reported agents. Immunomodulatory drugs emerged as substantial risk factors. These findings provide practical insights for clinicians managing patients with MC.

To report a case of AA developing during golimumab and leflunomide treatment for seropositive rheumatoid arthritis, with subsequent improvement following initiation of selective Janus kinase 1 (JAK1) inhibition...Upadacitinib was initiated for rheumatoid arthritis management and escalated from 15 mg to 30 mg...Although spontaneous remission and delayed corticosteroid effects cannot be excluded, the timing and magnitude of improvement support a temporal association with JAK1 inhibition. This case highlights a pragmatic therapeutic consideration when alopecia arises during TNF-α inhibitor therapy.

A 51-year-old woman with rheumatoid arthritis treated with rituximab and leflunomide presented with a 5-month history of malodorous vaginal discharge. Initial examination revealed vulvovaginitis and cervicitis, and she was treated with metronidazole and topical corticosteroids...Treatment with oral doxycycline led to rapid clinical and laboratory test improvement, and moxifloxacin was added for bactericidal coverage...Ureaplasma parvum should therefore be considered in patients presenting with sterile abscesses, systemic inflammation, and urogenital symptoms. Early recognition through molecular testing and targeted antimicrobial treatment can prevent prolonged morbidity and unnecessary surgical interventions.

P4, N=300, Active, not recruiting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting --> Active, not recruiting

Semi-quantitative histological scoring confirmed that LEES effectively limited articular structural damage without inducing the hepato-splenic toxicity associated with methotrexate. These findings indicate that LEES possesses multimodal immunomodulatory and analgesic actions with a highly favorable tolerability profile, supporting its further preclinical development as a potential adjunct or alternative to existing therapies.

Therefore, in the present study, a multifunctional nanoplatform, hollow mesoporous manganese dioxide (H-MnO2)-hemin-leflunomide@membrane (MHL@M), is proposed and fabricated...Both in vitro and in vivo results demonstrate that MHL@M has excellent tumor-targeting, TME-responsive, and ferroptosis activation capacities. This study provides a solid foundation for the development of ferroptosis-based therapeutic strategies for GBM.